Dr. Gurpreet Gill-Sangha joined RAB/CTEP as a Regulatory Affairs Professional in 2008. Before coming to NCI, she was a Senior Quality Reviewer and Biotechnology Unifying Designee (BUD) in the Division of Monoclonal Antibodies (DMA) in the Office of Biotechnology Products, Office of Pharmaceutical Sciences, CDER, FDA. Prior to joining DMA, Dr. Gill-Sangha was a senior reviewer in the Office of New Drug Quality Assessment, CDER, FDA and worked with several clinical divisions for the review and approval of regulatory submissions for small molecule drugs. In addition to the review of numerous Investigational New Drugs (INDs) and New Drug Applications (NDAs)/Biologic Licensure Applications (BLAs), Dr. Gill-Sangha conducted several FDA inspections of pharmaceutical firms. Prior to joining the FDA in 2000, Dr. Gill-Sangha was a Senior Scientist with a biotechnology device company, Sensors for Medicine and Science, Inc., in Gaithersburg, MD. Dr. Gill-Sangha was a post-doctoral fellow at Johns Hopkins University and earned her Ph.D. from State University of New York at Stony Brook.